Emmaus Life Sciences Inc (EMMA)

$0.07 +0.01 (22.78%)
Market Cap 4.77M
Revenue (ttm) 12.45M
Net Income (ttm) -7.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -60.16%
Debt to Equity Ratio -0.03
Volume 110,800
Avg Vol 169,826
Day's Range N/A - N/A
Shares Out 70.19M
Stochastic %K 70%
Beta 10.07
Analysts Strong Buy
Price Target $4.00

Company Profile

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. It has a license agreement with Kainos Medicine, Inc., which includes the patent rights o...

Industry: Biotechnology
Sector: Healthcare
Phone: 310 214 0065
Fax: 310 214 0075
Address:
21250 Hawthorne Boulevard, Suite 800, Torrance, United States
CEOBuysDisclosures
CEOBuysDisclosures Sep. 2 at 9:10 PM
$EMMA CEO purchased 530,767 shares at $0.03 for a total of $18,126. LEE WILLIS C now owns 1,326,485 shares. https://ceo-buys.com
0 · Reply
cheusmann
cheusmann Aug. 28 at 5:40 PM
$EMMA absolute banger and mash so far. Nobody talking about this one either. In since .02
0 · Reply
longtermopportunity
longtermopportunity Aug. 28 at 4:23 PM
$EMMA I was told this can go much higher .making money and licensing deals will continue to grow will lower expenses . Down 90% in last 5 years . Low float will be fun ride
0 · Reply
cheusmann
cheusmann Aug. 24 at 4:39 PM
$EMMA hmmmmmm
0 · Reply
Stock_Mama_Suz
Stock_Mama_Suz Aug. 20 at 3:35 PM
$EMMA this is currently the top % gainer of the day at 120% gain and a current s/p of .0285. Volume is over 10x the average 60 day volume. Signs point to at least something brewing behind the scenes.
1 · Reply
AlphaTuna
AlphaTuna Jun. 15 at 11:44 PM
Lowest Volume Rated General Stocks Per 6/15/2026’s Close: 1 – $SRNW 2 – $CIAFF 3 – $ATGFF 4 – $WHTCF 5 – $BLGVF 6 – $VPRB 7 – $MMXLF 8 – $YXT 9 – $NOVTU 10 – $EMMA https://optimizedvalue.xyz/daily-voltech-stock-etf-volume-technical-ratings-6-15-2026/
0 · Reply
AlphaTuna
AlphaTuna Sep. 3 at 12:53 AM
Lowest Volume Rated General Stocks Per 9/2/2025’s Close: 1 – $EMMA 2 – $OLNCF 3 – $AVHHL 4 – $LUXH 5 – $NBYCF 6 – $INBP 7 – $SISI 8 – $EMYB 9 – $CULL 10 – $AURX https://optimizedvalue.xyz/daily-voltech-stock-etf-volume-technical-ratings-9-2-2025/
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine May. 15 at 8:31 PM
$EMMA Q1 results show the double-edged sword of cost-cutting: Revenue dipped to $2.4M (-4% YoY) as generics bite, but operating loss narrowed to $1M. Cash reserves now at $1.3M - runway getting tight. The math remains brutal: sickle cell specialization vs generic tsunami and negative equity. Survival mode continues. https://www.prnewswire.com/news-releases/emmaus-life-sciences-reports-quarterly-financial-results-302457162.html
0 · Reply
d_risk
d_risk Apr. 14 at 11:02 PM
$EMMA - Emmaus Life Sciences, Inc. - 10K - Updated Risk Factors EMMA faces intensified risks in 2025: widened $9.3M loss, liquidity crunch with debt due and no refinancing, Endari’s U.S. exclusivity expired amid new generic competition and pricing pressure, regulatory setbacks, supply chain issues, and increased dilution and trading volatility risks. #Pharmaceuticals #MarketCompetition #SupplyChain #RegulatoryRisk #FinancialRisk 🟢 Added 🟠 Removed https://d-risk.ai/EMMA/10-K/2025-04-14
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Apr. 14 at 10:27 PM
$EMMA's 2024 results paint a grim picture: revenues plummeted 44% due to inventory mismanagement, now sitting on just $1.4M cash. While cost-cutting helped slightly, the $0.10/share loss and negative ops income reveal structural issues. CEO's 2025 optimism feels like rearranging deck chairs on the Titanic - especially with gene therapies looming. https://www.prnewswire.com/news-releases/emmaus-life-sciences-reports-2024-financial-results-302428165.html
0 · Reply
Latest News on EMMA
No data available.
CEOBuysDisclosures
CEOBuysDisclosures Sep. 2 at 9:10 PM
$EMMA CEO purchased 530,767 shares at $0.03 for a total of $18,126. LEE WILLIS C now owns 1,326,485 shares. https://ceo-buys.com
0 · Reply
cheusmann
cheusmann Aug. 28 at 5:40 PM
$EMMA absolute banger and mash so far. Nobody talking about this one either. In since .02
0 · Reply
longtermopportunity
longtermopportunity Aug. 28 at 4:23 PM
$EMMA I was told this can go much higher .making money and licensing deals will continue to grow will lower expenses . Down 90% in last 5 years . Low float will be fun ride
0 · Reply
cheusmann
cheusmann Aug. 24 at 4:39 PM
$EMMA hmmmmmm
0 · Reply
Stock_Mama_Suz
Stock_Mama_Suz Aug. 20 at 3:35 PM
$EMMA this is currently the top % gainer of the day at 120% gain and a current s/p of .0285. Volume is over 10x the average 60 day volume. Signs point to at least something brewing behind the scenes.
1 · Reply
AlphaTuna
AlphaTuna Jun. 15 at 11:44 PM
Lowest Volume Rated General Stocks Per 6/15/2026’s Close: 1 – $SRNW 2 – $CIAFF 3 – $ATGFF 4 – $WHTCF 5 – $BLGVF 6 – $VPRB 7 – $MMXLF 8 – $YXT 9 – $NOVTU 10 – $EMMA https://optimizedvalue.xyz/daily-voltech-stock-etf-volume-technical-ratings-6-15-2026/
0 · Reply
AlphaTuna
AlphaTuna Sep. 3 at 12:53 AM
Lowest Volume Rated General Stocks Per 9/2/2025’s Close: 1 – $EMMA 2 – $OLNCF 3 – $AVHHL 4 – $LUXH 5 – $NBYCF 6 – $INBP 7 – $SISI 8 – $EMYB 9 – $CULL 10 – $AURX https://optimizedvalue.xyz/daily-voltech-stock-etf-volume-technical-ratings-9-2-2025/
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine May. 15 at 8:31 PM
$EMMA Q1 results show the double-edged sword of cost-cutting: Revenue dipped to $2.4M (-4% YoY) as generics bite, but operating loss narrowed to $1M. Cash reserves now at $1.3M - runway getting tight. The math remains brutal: sickle cell specialization vs generic tsunami and negative equity. Survival mode continues. https://www.prnewswire.com/news-releases/emmaus-life-sciences-reports-quarterly-financial-results-302457162.html
0 · Reply
d_risk
d_risk Apr. 14 at 11:02 PM
$EMMA - Emmaus Life Sciences, Inc. - 10K - Updated Risk Factors EMMA faces intensified risks in 2025: widened $9.3M loss, liquidity crunch with debt due and no refinancing, Endari’s U.S. exclusivity expired amid new generic competition and pricing pressure, regulatory setbacks, supply chain issues, and increased dilution and trading volatility risks. #Pharmaceuticals #MarketCompetition #SupplyChain #RegulatoryRisk #FinancialRisk 🟢 Added 🟠 Removed https://d-risk.ai/EMMA/10-K/2025-04-14
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Apr. 14 at 10:27 PM
$EMMA's 2024 results paint a grim picture: revenues plummeted 44% due to inventory mismanagement, now sitting on just $1.4M cash. While cost-cutting helped slightly, the $0.10/share loss and negative ops income reveal structural issues. CEO's 2025 optimism feels like rearranging deck chairs on the Titanic - especially with gene therapies looming. https://www.prnewswire.com/news-releases/emmaus-life-sciences-reports-2024-financial-results-302428165.html
0 · Reply
mhaven2020
mhaven2020 Mar. 14 at 5:03 PM
$EMMA hey! Hello there beautiful! I'm here to play 😉
0 · Reply
insiderbuyingselling
insiderbuyingselling Sep. 18 at 4:09 PM
$EMMA new insider buying: 20000 shares. http://insiderbuyingselling.com/?t=EMMA
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Jul. 12 at 2:07 PM
$EMMA Emmaus Life Sciences Announces Outcome of FDA Inspection of Postmarketing Adverse Drug Experience Compliance Program
0 · Reply
Ernestpoe
Ernestpoe Jan. 29 at 7:07 PM
$EMMA bought a few shares along with TNBI. Go!
1 · Reply
risenhoover
risenhoover Dec. 20 at 11:01 AM
$EMMA / Emmaus Life Sciences files form 8-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 Emmaus Life Sci https://fintel.io/doc/sec-emmaus-life-sciences-inc-822370-8k-2023-december-20-19711-9312?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing
0 · Reply
risenhoover
risenhoover Dec. 20 at 12:45 AM
Insider Lim Seah H. reports buying 139,200 shares of $EMMA for a total cost of $30,916.00 https://fintel.io/n/us/emma/lim-seah-h?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=insider
0 · Reply
risenhoover
risenhoover Nov. 14 at 4:29 PM
$EMMA / Emmaus Life Sciences Incorporation files form 8-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Emmaus Life Sci https://fintel.io/doc/sec-emmaus-life-sciences-inc-822370-8k-2023-november-14-19675-6311?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing
0 · Reply
risenhoover
risenhoover Nov. 14 at 11:07 AM
$EMMA / Emmaus Life Sciences Incorporation files form 10-Q https://fintel.io/doc/sec-emmaus-life-sciences-inc-822370-10q-2023-november-14-19675-8232?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing
0 · Reply
macroaxis
macroaxis Sep. 8 at 5:01 AM
$QSI - Should I keep QuantumSi and Emmaus Life ( $EMMA ) in the same portfolio? Next fiscal quarter end is on 30th of September 2023 https://www.macroaxis.com/invest/pair-correlation/QSI/EMMA/QuantumSi-vs-Emmaus #portfolio_prospective #better_portfolio #diversify
0 · Reply
EarningsInsider
EarningsInsider Aug. 23 at 1:19 PM
Emmaus Life Sciences, Inc. Files SEC Form 8-K $EMMA https://www.marketbeat.com/stocks/OTCMKTS/EMMA/sec-filings/
0 · Reply
risenhoover
risenhoover Aug. 23 at 1:01 PM
$EMMA / Emmaus Life Sciences Incorporation files form 8-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2023 Emmaus Life Scien https://fintel.io/sf/us/emma?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing
0 · Reply